Testing and treating for Cryptococcal antigenemia is likely to be cost effective and has already been adopted at the national level in some countries, including Zimbabwe where since December 2016 it along with screening for tuberculosis (TB) has been recommended for all patients presenting with CD4 count less than 100cells/mm3, it is possible that testing patients with a CD4 count less than 200 cells/mm3 may yield additional cases [13,16–18]. Here, CD4 is linked to tuberculosis.